Готові списки джерел за темами / Therapeutic repositioning

Зміст

Статті в журналах
Дисертації
Частини книг
Тези доповідей конференцій

Добірка наукової літератури з теми "Therapeutic repositioning"

Автор: Grafiati

Опубліковано: 8 лютого 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Therapeutic repositioning".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Therapeutic repositioning"

Banno, Kouji, Miho Iida, Megumi Yanokura, Haruko Irie, Kenta Masuda, Yusuke Kobayashi, Eiichiro Tominaga, and Daisuke Aoki. "Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer." Scientific World Journal 2015 (2015): 1–10. http://dx.doi.org/10.1155/2015/341362.

Повний текст джерела

Анотація:

The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the results of previous clinical trials. New drugs for gynecologic tumors may be found by drug repositioning. For example, PPAR ligands may be effective against ovarian cancer, since PPAR activation eliminates COX-2 expression, arrests the cell cycle, and induces apoptosis. Metformin, an antidiabetic drug, is effective for endometrial cancer through inhibition of the PI3K-Akt-mTOR pathway by activating LKB1-AMPK and reduction of insulin and insulin-like growth factor-1 due to AMPK activation. COX-2 inhibitors for cervical cancer may also be examples of drug repositioning. PGE2 is induced in the arachidonate cascade by COX-2. PGE2 maintains high expression of COX-2 and induces angiogenic factors including VEGF and bFGF, causing carcinogenesis. COX-2 inhibitors suppress these actions and inhibit carcinogenesis. Combination therapy using drugs found by drug repositioning and current anticancer drugs may increase efficacy and reduce adverse drug reactions. Thus, drug repositioning may become a key approach for gynecologic cancer in drug discovery.

Стилі APA, Harvard, Vancouver, ISO та ін.

Yan, Ran, Jiahao He, Ge Liu, Jianfeng Zhong, Jiapeng Xu, Kai Zheng, Zhe Ren, Zhendan He, and Qinchang Zhu. "Drug Repositioning for Hand, Foot, and Mouth Disease." Viruses 15, no. 1 (December 27, 2022): 75. http://dx.doi.org/10.3390/v15010075.

Повний текст джерела

Анотація:

Hand, foot, and mouth disease (HFMD) is a highly contagious disease in children caused by a group of enteroviruses. HFMD currently presents a major threat to infants and young children because of a lack of antiviral drugs in clinical practice. Drug repositioning is an attractive drug discovery strategy aimed at identifying and developing new drugs for diseases. Notably, repositioning of well-characterized therapeutics, including either approved or investigational drugs, is becoming a potential strategy to identify new treatments for virus infections. Various types of drugs, including antibacterial, cardiovascular, and anticancer agents, have been studied in relation to their therapeutic potential to treat HFMD. In this review, we summarize the major outbreaks of HFMD and the progress in drug repositioning to treat this disease. We also discuss the structural features and mode of action of these repositioned drugs and highlight the opportunities and challenges of drug repositioning for HFMD.

Стилі APA, Harvard, Vancouver, ISO та ін.

Cuéllar Rodríguez, Santiago. "Therapeutic repositioning: importance of new therapeutic indications approved for old medicines." Anales de la Real Academia Nacional de Farmacia, no. 90(02) (July 1, 2024): 239–56. http://dx.doi.org/10.53519/analesranf.2024.90.02.06.

Повний текст джерела

Анотація:

In the field of health and, particularly in biomedicine, continuous reevaluation has allowed us to see with a different attitude what was apparently known; A large part of the medicines from synthetic chemistry, biotechnology and advanced therapies (genetics, somatics, tissue engineering, etc.) are a clear example of this. The search and investigation of new applications for drugs already approved and in clinical use – and even for compounds that did not reach the clinical research phases at the time – is usually called “repositioning”, which makes it possible to have drugs with a profile of safety and efficacy already known, which represents a significant saving in time and development costs and, sometimes, is the only way to develop therapies for rare diseases, as orphan indications. In fact, it is estimated that a substantial part of the known drugs may have new therapeutic uses and that drugs currently in clinical use could be used for numerous applications other than those for which they were originally approved. The high number of authorizations of new indications or their extensions or modifications by the EMA and the FDA, in relation to that of medicines with new active ingredients, highlights that pharmacological research – basic and clinical – does not end with the marketing authorization of a medicine but, on the contrary, there are many that continue to be the subject of extensive and intensive research by their titular laboratories in order to extract the maximum knowledge and health results from products whose development has a very high economic cost and requires large and multidisciplinary human research teams. In order to examine the current innovative activity in the field of new indications for medicines previously authorized in the European Union, we have proceeded to systematically collect and study the contents of all the summaries of the 36 plenary meetings of the Committee for Medicinal Products for Human Use (CHMP) published by the EMA between January 2021 and March 2024, in which 258 positive recommendations for extension of indications were made, for a total of 181 medicines from 74 laboratories. Keywords: Pharmacology; therapeutic repositioning; clinical research; drug authorization; drug evaluation

Стилі APA, Harvard, Vancouver, ISO та ін.

Kwon, Minsu. "Drug Repositioning for Treatment of Head and Neck Cancers." Korean Journal of Otorhinolaryngology-Head and Neck Surgery 66, no. 8 (August 25, 2023): 505–13. http://dx.doi.org/10.3342/kjorl-hns.2023.00731.

Повний текст джерела

Анотація:

Head and neck cancer (HNC) is a complex disease that poses significant therapeutic challenges. Traditional treatment options such as surgery, radiation, and chemotherapy have limited efficacy and often result in significant side effects. In recent years, drug repositioning has emerged as a promising strategy to identify new therapeutic options for HNC. Drug repositioning involves repurposing existing drugs, already approved for other indications, for the treatment of HNC. This approach takes advantage of existing knowledge about drug safety and efficacy, reducing the time and cost needed to develop new drugs. By leveraging the known safety profiles, pharmacokinetic, and pharmacodynamic properties of these drugs, drug repositioning can accelerate the drug development process and reduce costs. In this review, the current status of drug repositioning efforts for HNC and the challenges and opportunities associated with this approach are discussed. We also highlight some of the most promising drug candidates that have emerged from recent studies and clinical trials. Overall, drug repositioning has the potential to significantly improve the treatment landscape for HNC and offer new hope for patients with this challenging disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

Perwitasari, Olivia, Abhijeet Bakre, S. Tompkins, and Ralph Tripp. "siRNA Genome Screening Approaches to Therapeutic Drug Repositioning." Pharmaceuticals 6, no. 2 (January 28, 2013): 124–60. http://dx.doi.org/10.3390/ph6020124.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ruckenstein, Michael J. "Therapeutic Efficacy of the Epley Canalith Repositioning Maneuver." Laryngoscope 111, no. 6 (June 2001): 940–45. http://dx.doi.org/10.1097/00005537-200106000-00003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hu, Qingkai, Xianfang Wang, Yifeng Liu, Yu Sang, and Dongfang Zhang. "Application of artificial intelligence in drug repositioning." Gene & Protein in Disease 1, no. 3 (November 7, 2022): 201. http://dx.doi.org/10.36922/gpd.v1i3.201.

Повний текст джерела

Анотація:

The use of artificial intelligence technologies in biology, pharmacy, and medicine has brought about a dramatic change in these industries. Drug repositioning is a method of drug development in the process of applying existing therapeutic agents to new diseases. This paper first outlines the use of artificial intelligence technology in the field of drug repositioning, then reviews a variety of application methods of artificial intelligence in the realm of drug repositioning, and finally summarizes the advantages and disadvantages of these methods, and proposes the difficulties faced by artificial intelligence in drug repositioning in the future and the corresponding suggestions to achieve the goal of helping researchers to develop more effective methods of drug repositioning.

Стилі APA, Harvard, Vancouver, ISO та ін.

Marrazzo, Pasquale, and Cian O’Leary. "Repositioning Natural Antioxidants for Therapeutic Applications in Tissue Engineering." Bioengineering 7, no. 3 (September 2, 2020): 104. http://dx.doi.org/10.3390/bioengineering7030104.

Повний текст джерела

Анотація:

Although a large panel of natural antioxidants demonstrate a protective effect in preventing cellular oxidative stress, their low bioavailability limits therapeutic activity at the targeted injury site. The importance to deliver drug or cells into oxidative microenvironments can be realized with the development of biocompatible redox-modulating materials. The incorporation of antioxidant compounds within implanted biomaterials should be able to retain the antioxidant activity, while also allowing graft survival and tissue recovery. This review summarizes the recent literature reporting the combined role of natural antioxidants with biomaterials. Our review highlights how such functionalization is a promising strategy in tissue engineering to improve the engraftment and promote tissue healing or regeneration.

Стилі APA, Harvard, Vancouver, ISO та ін.

Lee, Soojung, Judee Grace E. Nemeño, and Jeong Ik Lee. "Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration." Tissue Engineering Part B: Reviews 22, no. 5 (October 2016): 341–57. http://dx.doi.org/10.1089/ten.teb.2015.0300.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Shibata, Kyoko, Toshinori Endo, and Yoshikazu Kuribayashi. "Computational Drug-repositioning Approach Identifying Sirolimus as a Potential Therapeutic Option for Inflammatory Dilated Cardiomyopathy." Drug Research 69, no. 10 (June 25, 2019): 565–71. http://dx.doi.org/10.1055/a-0950-9608.

Повний текст джерела

Анотація:

Abstract Objective The aim of this study was to determine promising treatment options for human inflammatory dilated cardiomyopathy using a computational drug-repositioning approach (repurposing established drug compounds for new therapeutic indications). Background If the myocardial tissue is detected to be infiltrated with inflammatory cells, primarily of lymphocytes, and if the virus is confirmed using genetic examination (PCR) or immunostaining, the infection is suspected. However, there is no specific treatment (i. e., an antiviral drug) even if the virus is identified; therefore, we used Connectivity Map to identify compounds showing inverse drug–disease signatures, indicating activity against inflammatory dilated cardiomyopathy. Results Potential drug-repositioning candidates for the treatment of inflammatory dilated cardiomyopathy were explored through a systematic comparison of the gene expression profiles induced by drugs using Gene Expression Omnibus and Connectivity Map databases. Conclusion Using a computational drug-repositioning approach based on the integration of publicly available gene expression signatures of drugs and diseases, sirolimus was suggested as a novel therapeutic option for inflammatory dilated cardiomyopathy.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Therapeutic repositioning"

DE, FLORIAN FANIA ROSSELLA. "Identification and characterization of therapeutic molecules affecting expression levels of the tumor suppressor DAB2IP in cancer." Doctoral thesis, Università degli Studi di Trieste, 2023. https://hdl.handle.net/11368/3042421.

Повний текст джерела

Анотація:

In tumors, the reciprocal communication between malignant cells and non-transformed stromal cells involves a variety of signaling proteins and modulators that cooperate to control proliferation, migration and apoptosis. Among them, the tumor suppressor DAB2IP, a Ras-GAP and signaling adaptor protein, modulates signal transduction in response to several extracellular stimuli, negatively regulating multiple oncogenic pathways. Accordingly, the loss of DAB2IP in tumor cells fosters metastasis and enhances chemo- and radio-resistance. DAB2IP is rarely mutated in cancer but is frequently downregulated or inactivated by multiple mechanisms. Solid experimental evidences indicate that DAB2IP reactivation can reduce cancer aggressiveness in tumors driven by multiple different oncogenic mutations. In this regard, we showed that the ectopic overexpression of DAB2IP is sufficient to significantly affect the behavior of prostate cancer cells, possibly slowing tumor dissemination. All these evidences indicate DAB2IP as a strong target for anti-cancer therapy. Nevertheless, therapeutic approaches to increase DAB2IP function in cancer are still not available. Based on these observations, we performed a high-throughput screening with more than 1200 FDA- approved drugs to search for molecules that increase DAB2IP protein levels. Since detection of endogenous DAB2IP is technically difficult due to relatively low expression levels and the limitations of available antibodies, we exploited CRISPR/Cas9 gene editing to generate two prostate cancer cell models expressing endogenous DAB2IP fused to HiBiT, a peptide tag that enabled luminescence- based detection of protein levels in a sensitive and quantitative manner. Using this approach, we identified a set of candidate drugs able to increase DAB2IP levels. We focused our attention on the three more effective drugs: one antibacterial, one antileukemic and one antiasthmatic. Although not conclusive, functional experiments indicate that DAB2IP-upregulating drugs can inhibit some cancer-associated phenotypes, and that some of these effects are at least in part dependent on DAB2IP. These findings, if further confirmed, may suggest a potential repurposing of these drugs for solid cancers’ treatment, as support to current therapies.
In tumors, the reciprocal communication between malignant cells and non-transformed stromal cells involves a variety of signaling proteins and modulators that cooperate to control proliferation, migration and apoptosis. Among them, the tumor suppressor DAB2IP, a Ras-GAP and signaling adaptor protein, modulates signal transduction in response to several extracellular stimuli, negatively regulating multiple oncogenic pathways. Accordingly, the loss of DAB2IP in tumor cells fosters metastasis and enhances chemo- and radio-resistance. DAB2IP is rarely mutated in cancer but is frequently downregulated or inactivated by multiple mechanisms. Solid experimental evidences indicate that DAB2IP reactivation can reduce cancer aggressiveness in tumors driven by multiple different oncogenic mutations. In this regard, we showed that the ectopic overexpression of DAB2IP is sufficient to significantly affect the behavior of prostate cancer cells, possibly slowing tumor dissemination. All these evidences indicate DAB2IP as a strong target for anti-cancer therapy. Nevertheless, therapeutic approaches to increase DAB2IP function in cancer are still not available. Based on these observations, we performed a high-throughput screening with more than 1200 FDA- approved drugs to search for molecules that increase DAB2IP protein levels. Since detection of endogenous DAB2IP is technically difficult due to relatively low expression levels and the limitations of available antibodies, we exploited CRISPR/Cas9 gene editing to generate two prostate cancer cell models expressing endogenous DAB2IP fused to HiBiT, a peptide tag that enabled luminescence- based detection of protein levels in a sensitive and quantitative manner. Using this approach, we identified a set of candidate drugs able to increase DAB2IP levels. We focused our attention on the three more effective drugs: one antibacterial, one antileukemic and one antiasthmatic. Although not conclusive, functional experiments indicate that DAB2IP-upregulating drugs can inhibit some cancer-associated phenotypes, and that some of these effects are at least in part dependent on DAB2IP. These findings, if further confirmed, may suggest a potential repurposing of these drugs for solid cancers’ treatment, as support to current therapies.

Стилі APA, Harvard, Vancouver, ISO та ін.

Almyre, Claire. "Syndrome de Barth et recherche de voies thérapeutiques." Electronic Thesis or Diss., Bordeaux, 2024. http://www.theses.fr/2024BORD0320.

Повний текст джерела

Анотація:

Les maladies mitochondriales sont diverses, pléiotropes, graves et en grande partie sans traitement. Parmi elles, le syndrome de Barth (BTHS - Barth Syndrome) qui est une cardiomyopathie rare liée à l’X, est causée par des mutations dans le gène nucléaire TAZ, encodant la tafazzine. Cette dernière est une acyltransférase impliquée dans la maturation de la cardiolipine (CL), un phospholipide clé pour les mitochondries, optimisant le fonctionnement de la phosphorylation oxydative (OXPHOS) pour la production d’ATP. Un tel défaut entraîne des signes cliniques pouvant aller jusqu’à la mort.Pour faciliter la découverte de molécules thérapeutiques, nous avons mis au point une méthode de criblage, simple et rapide, via un modèle levure S. cerevisiae du BTHS, qui récapitule les dysfonctionnements cellulaires et mitochondriaux observés chez l’homme. Cette méthode vise à identifier des candidats médicaments, au moins en phase II de tests cliniques, qui améliorent les fonctions mitochondriales de ce modèle. Notre approche est donc celle d’un repositionnement thérapeutique. J’ai ainsi isolé deux candidats médicaments : le disulfiram (DSF) et l’ebselen (EBS), pour lesquels j’ai validé les effets bénéfiques sur des cellules de patients atteints du BTHS. Enfin, j’ai montré que l’EBS améliore l’endurance et les fonctions mitochondriales cardiaques d’un modèle murin du BTHS. Les tests précliniques chez la souris sont en cours avec le DSF. J’ai aussi découvert que ces candidats médicaments ont la capacité de restaurer les fonctions mitochondriales d’un large panel de modèles levure et humain d'autres pathologies mitochondriales.J’ai par la suite cherché à comprendre les mécanismes d’action de ces composés dans le contexte des pathologies mitochondriales. Le DSF est utilisé dans le traitement de l’alcoolisme via son action inhibitrice de l’aldéhyde déshydrogénase (ALDH). Dans notre contexte, l’action de sauvetage du DSF est due à une autre propriété : sa capacité à transporter le cuivre au travers des membranes biologiques et ainsi augmenter la teneur en cuivre dans la mitochondrie pour favoriser et stimuler l'assemblage du complexe IV. L’EBS est actuellement en phase III de tests cliniques contre les troubles bipolaires pour sa capacité à inhiber l’inositol monophosphatase (IMP) et contre la maladie de Ménière pour ses propriétés antioxydantes. Dans notre cas, l’action de sauvetage de l’EBS implique (i) une régulation à la baisse de la traduction cytosolique pour restaurer l'homéostasie protéique entre le cytosol et les mitochondries, et (ii) une stimulation du cycle de Krebs via la pyruvate déshydrogénase (PDH) pour augmenter le rendement en ATP. Ces deux effets seraient dépendants de mTOR, un complexe situé dans les lysosomes où l'EBS s'accumule, et connu pour agir à la fois sur la PDH et la synthèse protéique cytosolique.Ces résultats ouvrent la voie à de nouvelles stratégies thérapeutiques pour le syndrome de Barth, mais également pour d’autres pathologies mitochondriales
Mitochondrial diseases are diverse, pleiotropic, severe and largely untreatable. Among them, Barth syndrome (BTHS), a rare X-linked cardiomyopathy, is caused by mutations in the nuclear gene TAZ, encoding the protein tafazzin. Tafazzine is an acyltransferase involved in the maturation of cardiolipin (CL), a key phospholipid for mitochondria, optimising oxidative phosphorylation (OXPHOS) for ATP production. Such a defect leads to severe clinical signs that can even result in death.To facilitate the discovery of therapeutic molecules, we have developed a simple and rapid screening method using a yeast S. cerevisiae model of BTHS, which recapitulates the cellular and mitochondrial dysfunctions observed in humans. The aim of this method is to identify drug candidates, at least in phase II clinical trials, that improve the mitochondrial functions of this model. Our approach is therefore one of therapeutic repositioning. I have isolated two drug candidates, disulfiram (DSF) and ebselen (EBS), and validated their beneficial effects on cells derived from BTHS patients. Finally, I have shown that EBS improves endurance and cardiac mitochondrial function in a mouse model of BTHS. Preclinical tests in mice are underway with DSF. I also discovered that these drug candidates have the capacity to restore mitochondrial function in a wide range of yeast and human models of other mitochondrial pathologies.I then sought to understand the mechanisms of action of these compounds in the context of mitochondrial pathologies. DSF is used in the treatment of alcoholism through its inhibitory action on aldehyde dehydrogenase (ALDH). In our context, DSF’s beneficial effect is due to another property: its ability to transport copper across biological membranes, thereby increasing the copper content in mitochondria to promote and stimulate the assembly of complex IV. EBS is currently in phase III clinical trials against bipolar disorder for its ability to inhibit inositol monophosphatase (IMP) and against Meniere's disease for its antioxidant properties. In our case, the rescuing activity of EBS involves (i) a down-regulation of cytosolic translation to restore protein homeostasis between the cytosol and mitochondria, and (ii) a stimulation of the Krebs cycle through the pyruvate dehydrogenase (PDH) to increase ATP yield. These two effects are thought to be dependent on mTOR, a complex located in the lysosomes where EBS accumulates, and known to act on both PDH and cytosolic protein synthesis.These results pave the way for new therapeutic strategies, not only for Barth syndrome, but also for other mitochondrial diseases

Стилі APA, Harvard, Vancouver, ISO та ін.

Chuang, Kun-Lin, and 莊昆霖. "Using synthetic lethality to predict therapeutic biomarkers for drug repositioning and drug discovery." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/439xqx.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Vale, Cátia Daniela Pereira. "Velhas terapêuticas para novas aplicações: o reposicionamento de fármacos como estratégia de desenvolvimento." Master's thesis, 2019. http://hdl.handle.net/10316/88361.

Повний текст джерела

Анотація:

Relatório de Estágio do Mestrado Integrado em Ciências Farmacêuticas apresentado à Faculdade de Farmácia
O reposicionamento de fármacos consiste na pesquisa e identificação de novas indicações terapêuticas para fármacos já conhecidos. Aparece como uma alternativa para combater a estagnação da investigação e desenvolvimento de novos medicamentos, por parte da indústria farmacêutica nos últimos anos. O seu desenvolvimento clínico requer menos tempo e menos etapas, visto que o perfil de segurança do medicamento já é conhecido e demonstrado, assim como um investimento mais baixo. A pesquisa das novas indicações terapêuticas pressupõe abordagens experimentais e computacionais para se gerarem as hipóteses de interações fármaco-alvo desconhecidas até então. Estas baseiam-se em dados genómicos, proteómicos, estruturais, fenotípicos, de ligações químicas, de semelhanças entre fármacos, de mecanismos de ação, de indicações off-label e de informações de farmacovigilância, de ensaios clínicos e relatadas por pacientes e profissionais de saúde, em registos eletrónicos. As áreas com maior carência de medicamentos são a oncologia e as doenças raras, pelo que têm no reposicionamento uma esperança em encontrar fármacos eficazes. Para isto ser possível, é fundamental a criação de parcerias entre instituições académicas, instituições de pesquisa biotecnológica e indústrias farmacêuticas, para se aumentar a pesquisa e os investimentos proporcionados, assim como o aumento de financiamentos por parte dos governos. Já existem algumas parcerias e financiamentos para incentivar a pesquisas, mas ainda em número insuficiente. Além disso, já há também fármacos colocados no mercado pela via do reposicionamento. Contudo, ainda há alguns fatores que dificultam o reposicionamento e a entrada dos fármacos reposicionados no mercado, nomeadamente os aspetos relacionados com a falta de investimento e as patentes que protegem os medicamentos.
The repositioning of drugs consists of the research and identification of new therapeutic indications for drugs already known. It appears as an alternative to counteract the stagnation of research and development of new drugs by the pharmaceutical industry in recent years. Its clinical development requires less time and fewer steps, since the safety profile of the drug is already known and demonstrated, as well as a lower investment. The research of the new therapeutic indications presupposes experimental and computational approaches to generate the hypotheses of unknown drug-target interactions until then. These are based on genomic, proteomic, structural, phenotypic, chemical bonding, drug-like, action-mechanism, off-label indications and pharmacovigilance information from clinical trials and reported by patients and health professionals, in electronic records. The areas with the greatest lack of medicines are oncology and rare diseases, so they have in repositioning a hope of finding effective drugs. For this to be possible, partnerships between academic institutions, biotechnological research institutions and pharmaceutical industries are essential to increase research and investment, as well as increased funding from governments. There are already some partnerships and funding to encourage research, but still insufficient. In addition, there are also drugs placed on the market through repositioning. However, there are still some factors that hinder the repositioning and entry of repositioned drugs in the market, namely the aspects related to the lack of investment and the patents that protect the medicines.

Стилі APA, Harvard, Vancouver, ISO та ін.

Panagis, Lana. "Chiropractic manipulative therapy and proprioceptive neck exercises for the treatment of chronic mechanical neck pain and its effect on head repositioning accuracy." Thesis, 2013. http://hdl.handle.net/10210/8767.

Повний текст джерела

Анотація:

M.Tech. (Chiropractic)
Mechanical neck pain is the most common type of cervical spine pain encountered. It is also referred to as simple or non-specific neck pain and is common in all groups of people (Plaugher, 1993). A majority of individuals with neck pain do not experience a resolution in their pain and disability and this thus results in chronicity (Cote, Cassidy, Carrol and Kristman, 2004). Chiropractic manipulative therapy (CMT) is a specific form of articular manipulation, especially of the vertebral column. This is performed either manually, mechanically, actively or passively in order to restore normal articular alignment and function (Gatterman, 2005). Proprioceptive neck exercises are designed to retrain the cervical musculature to regain its position sense in space. Specific exercises are designed to locate the head to a neutral position and then to do a series of movements in other planes, and then to return the head to the neutral position (Revel, Minguet, Gergoy, Valliant and Manuel, 1994). Chiropractic manipulative therapy does have documented positive effects on the proprioceptive system within the cervical spine (Palmgren, 2006) as does proprioceptive exercises (Sarig-Bahat, 2003; Revel, Minguet, Gergoy, Vaillant, Manuel, 1994). The desired effects of combining both these treatments would be to increase the response rate in patients suffering from chronic mechanical neck pain. The aim of this study was to compare the effects of Chiropractic manipulative therapy (CMT) and proprioceptive neck exercises as stand-alone treatment protocols, as well as a combination treatment protocol with regards to neck pain, disability, cervical spine range of motion and Head Repositioning Accuracy (HRA). Participants were recruited from the University of Johannesburg Chiropractic Day Clinic. They were eligible to participate in the study once they met the inclusion and exclusion criteria. Participants were recruited by means of advertisements that were placed around the respective campuses of the University of Johannesburg as well as by word of mouth. Thirty participants, who presented with chronic mechanical neck pain, volunteered for this randomised comparative clinical study. The participants, aged between 18 - 40, were randomly divided into three groups of ten, with a half female to male ratio. Group 1 received Chiropractic manipulative therapy to the restricted joints in the cervical spine, Group 2 received proprioceptive neck exercises and Group 3 received a combination of both treatments. Participants were treated for a total of 6 visits over a three week period. Subjective and objective measurements were taken at the beginning of visits 1, 4 and at a final visit 7 during which only measurements were taken. Subjective measurements consisted of the Vernon-Mior Neck Pain and Disability Index (VMNPDI) and the Numerical Pain Rating Scale (NPRS) to assess the participants‟ neck pain and disability as well as their perception of pain. Objective measurements were obtained by using the Cervical Range of Motion device (CROM) as well as measuring the Head Repositioning Accuracy (HRA) as described by Revel, Andre-Deshays and Minguet (1991). Based on the results of the study, it could be concluded that both Group 1 (Chiropractic manipulative therapy to the restricted joints in the cervical spine) and Group 3 (a combination of cervical spine manipulation and proprioceptive neck exercises) can be used effectively to treat chronic mechanical neck pain and improve HRA. Group 1, 2 and 3 showed statistical improvements in certain areas and clinical improvements in all areas over time. It could not be statistically concluded whether one treatment is superior to the other, although clinically, Group 1 and Group 3 seemed to be more effective. Considering that Group 3 is a combination of cervical spine manipulation and proprioceptive neck exercises, it could be considered as a valid treatment protocol for chronic mechanical neck pain and improving HRA and could thus be used in a clinical setting.

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Therapeutic repositioning"

Orr-Burks, Nichole, Byoung-Shik Shim, Olivia Perwitasari, and Ralph A. Tripp. "RNAi Screening toward Therapeutic Drug Repurposing." In Drug Repositioning, 105–20. Boca Raton: CRC Press, [2017] | Series: Frontiers in Neurotherapeutics series: CRC Press, 2017. http://dx.doi.org/10.4324/9781315373669-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Re, Matteo, and Giorgio Valentini. "Large Scale Ranking and Repositioning of Drugs with Respect to DrugBank Therapeutic Categories." In Bioinformatics Research and Applications, 225–36. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-30191-9_21.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Reaume, Andrew G., and Christopher A. Lipinski. "Chapter 12. Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers." In Drug Discovery, 217–32. Cambridge: Royal Society of Chemistry, 2020. http://dx.doi.org/10.1039/9781839160721-00217.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Jia, Zhilong, Xinyu Song, Jinlong Shi, Weidong Wang, and Kunlun He. "Gene Signature-Based Drug Repositioning." In Drug Repurposing - Molecular Aspects and Therapeutic Applications [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.101377.

Повний текст джерела

Анотація:

With the advent of dynamical omics technology, especially the transcriptome and proteome, a huge amount of data related to various diseases and approved drugs are available under multi global projects or researches with their interests. These omics data and new machine learning technology largely promote the translation of drug research into clinical trials. We will cover the following topics in this chapter. 1) An introduction to the basic discipline of gene signature-based drug repurposing; 2) databases of genes, drugs and diseases; 3) gene signature databases of the approved drugs; 4) gene signature databases of various diseases; 5) gene signature-based methods and tools for drug repositioning; 6) new omics technology for drug repositioning; 7) drug repositioning examples with reproducible code. And finally, discuss the future trends and conclude.

Стилі APA, Harvard, Vancouver, ISO та ін.

Rudrapal, Mithun, Shubham J. Khairnar, and Anil G. Jadhav. "Drug Repurposing (DR): An Emerging Approach in Drug Discovery." In Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.93193.

Повний текст джерела

Анотація:

Drug repurposing (DR) (also known as drug repositioning) is a process of identifying new therapeutic use(s) for old/existing/available drugs. It is an effective strategy in discovering or developing drug molecules with new pharmacological/therapeutic indications. In recent years, many pharmaceutical companies are developing new drugs with the discovery of novel biological targets by applying the drug repositioning strategy in drug discovery and development program. This strategy is highly efficient, time saving, low-cost and minimum risk of failure. It maximizes the therapeutic value of a drug and consequently increases the success rate. Thus, drug repositioning is an effective alternative approach to traditional drug discovery process. Finding new molecular entities (NME) by traditional or de novo approach of drug discovery is a lengthy, time consuming and expensive venture. Drug repositioning utilizes the combined efforts of activity-based or experimental and in silico-based or computational approaches to develop/identify the new uses of drug molecules on a rational basis. It is, therefore, believed to be an emerging strategy where existing medicines, having already been tested safe in humans, are redirected based on a valid target molecule to combat particularly, rare, difficult-to-treat diseases and neglected diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

Tamai, Sho, Nozomi Hirai, Shabierjiang Jiapaer, Takuya Furuta, and Mitsutoshi Nakada. "Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective." In Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.92803.

Повний текст джерела

Анотація:

Gliomas are the most common primary brain tumors. Among them, glioblastoma (GBM) possesses the most malignant phenotype. Despite the current standard therapy using an alkylating anticancer agent, temozolomide, most patients with GBM die within 2 years. Novel chemotherapeutic agents are urgently needed to improve the prognosis of GBM. One of the solutions, drug repositioning, which broadens the indications of existing drugs, has gained attention. Herein, we categorize candidate agents, which are newly identified as therapeutic drugs for malignant glioma into 10 classifications based on these original identifications. Some drugs are in clinical trials with hope. Additionally, the obstacles, which should be overcome in order to accomplish drug repositioning as an application for GBM and the future perspectives, have been discussed.

Стилі APA, Harvard, Vancouver, ISO та ін.

Hosseini, Fatemeh, Mehrdad Azin, Hamideh Ofoghi, and Tahereh Alinejad. "Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential SARS-CoV-2 Viral Inhibitors." In Drug Repurposing - Molecular Aspects and Therapeutic Applications [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101395.

Повний текст джерела

Анотація:

Unfortunately, to date, there is no approved specific antiviral drug treatment against COVID-19. Due to the costly and time-consuming nature of the de novo drug discovery and development process, in recent days, the computational drug repositioning method has been highly regarded for accelerating the drug-discovery process. The selection of drug target molecule(s), preparation of an approved therapeutics agent library, and in silico evaluation of their affinity to the subjected target(s) are the main steps of a molecular docking-based drug repositioning process, which is the most common computational drug re-tasking process. In this chapter, after a review on origin, pathophysiology, molecular biology, and drug development strategies against COVID-19, recent advances, challenges as well as the future perspective of molecular docking-based drug repositioning for COVID-19 are discussed. Furthermore, as a case study, the molecular docking-based drug repurposing process was planned to screen the 3CLpro inhibitor(s) among the nine Food and Drug Administration (FDA)-approved antiviral protease inhibitors. The results demonstrated that Fosamprenavir had the highest binding affinity to 3CLpro and can be considered for more in silico, in vitro, and in vivo evaluations as an effective repurposed anti-COVID-19 drug.

Стилі APA, Harvard, Vancouver, ISO та ін.

Khute, Sulekha, Kareti Srinivasa Rao, and Paranthaman Subash. "Computational Drug Repositioning Method Applied to Lung Cancer." In Repurposed Drugs - Current State and Future Perspectives [Working Title]. IntechOpen, 2025. https://doi.org/10.5772/intechopen.1006611.

Повний текст джерела

Анотація:

Lung cancer is the most common cancer affecting men and women worldwide. Among different types of lung cancer (LC), two primary forms stand out: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). NSCLC, the more prevalent variety, accounts for around 85–90% of all lung cancer cases. Drug repurposing, also known as drug repositioning, is the investigation of using existing drugs for new therapeutic purposes. This approach can lead to the formulation of effective treatments for diseases that might not have been adequately addressed by traditional drug discovery methods. The importance of drug repositioning in lung cancer research cannot be overstated. Traditional drug discovery is often a lengthy and costly process, requiring years of research and substantial investment. In contrast, repurposing existing medications can enhance the pre-clinical journey of developing new drugs. High-performance computing capabilities enable the efficient processing of these extensive datasets, which may include biological, biomedical, and electronic health-related information. This data-driven approach has dramatically accelerated the development of computational methods for drug repositioning. The strategy of drug repositioning offers a promising pathway for researchers, significantly shortening the timeline and reducing the costs associated with new drug development.

Стилі APA, Harvard, Vancouver, ISO та ін.

Dhir, Neha, Ashish Jain, Dhruv Mahendru, Ajay Prakash, and Bikash Medhi. "Drug Repurposing and Orphan Disease Therapeutics." In Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.91941.

Повний текст джерела

Анотація:

Drug repurposing (or drug repositioning) is an innovative way to find out the new indications of a drug that already exists in the market with known therapeutic indications. It offers an effective way to drug developers or the pharmaceutical companies to identify new targets for FDA-approved drugs. Less time consumption, low cost and low risk of failure are some of the advantages being offered with drug repurposing. Sildenafil (Viagra), a landmark example of a repurposed drug, was introduced into the market as an antianginal drug. But at present, its use is repurposed as drug for erectile dysfunction. In a similar way, numerous drugs are there that have been successfully repurposed in managing the clinical conditions. The chapter would be highlighting the various drug repurposing strategies, drugs repurposed in the past and the current status of repurposed drugs in the orphan disease therapeutics along with regulatory guidelines for drug repurposing.

Стилі APA, Harvard, Vancouver, ISO та ін.

Lambrescu, Ioana, Emilia Manole, Laura Cristina Ceafalan, and Gisela Gaina. "The Potential Benefits of Drug-Repositioning in Muscular Dystrophies." In Advances in Muscular Dystrophy Research - From Cellular and Molecular Basis to Therapies [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.110714.

Повний текст джерела

Анотація:

Muscular dystrophies (MDs) are a complex group of rare neuromuscular disorders caused by genetic mutations that progressively weaken the muscles, resulting in an increasing level of disability. The underlying cause of these conditions consists of mutations in the genes in charge of a person’s muscle composition and functionality. MD has no cure, but medications and therapy can help control symptoms and slow the disease’s progression. Effective treatments have yet to be developed, despite the identification of the genetic origins and a thorough knowledge of the pathophysiological alterations that these illnesses induce. In this scenario, there is an urgent need for novel therapeutic options for these severe illnesses, and drug repositioning might be one feasible answer. In other words, drug repositioning/repurposing is an accelerated method of developing novel pharmaceuticals since the new indication is based on previously accessible safety, pharmacokinetic, and manufacturing data. This is particularly crucial for individuals with life-threatening illnesses such as MDs, who cannot wait for a conventional medication development cycle. This chapter aims to review the challenges and opportunities of drug-repositioning in a variety of MDs to establish novel treatment approaches for these incurable diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Therapeutic repositioning"

Paci, Paola, and Joseph Loscalzo. "Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects." In RExPO23. REPO4EU, 2023. http://dx.doi.org/10.58647/rexpo.23022.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Doudican, Nicole A., Shireen Vali, Shweta Kapoor, Anay Talawdekar, Zeba Sultana, Taher Abbasi, Gautam Sethi, Seth J. Orlow, and Amitabha Mazumder. "Abstract 2104: In vitro validation of rationally designed therapeutic based on drug repositioning and combinations." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2104.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Phillips, Lyn. "Pressure Ulcer Prevention: Keep it Safe, Keep it Simple!" In Applied Human Factors and Ergonomics Conference. AHFE International, 2021. http://dx.doi.org/10.54941/ahfe100475.

Повний текст джерела

Анотація:

Pressure Ulcer (PU) Prevention Guidelines typically recommend that vulnerable patients be physically repositioned every 2-4 hours, although the risk of caregiver injury is rarely discussed. Some guidelines, concerned with the fabric and construction of slings, continue to mandate the removal of lift equipment from beneath the patient after use and, despite a weak evidence base, this might lessen repositioning frequency and discourage safe practice. A pragmatic solution may be a flexible, breathable, quick-drying, low-friction lift sheet, designed to work in synergy with a pressure-redistributing mattress and which replaces the standard sheet. A series of standardised laboratory tests compared key performance characteristics of two sheet textiles: a 100% cotton hospital bed sheet and the Maxi Transfer™ sheet, a novel synthetic lift sheet. Results showed that when compared to the cotton sheet, the synthetic sheet was more breathable, had lower heat retention properties, superior wicking and better synergy with the therapeutic mattress. Regular repositioning, the cornerstone of PU prevention, is most likely to occur when clinicians have immediate access to lifting equipment. Replacing the standard bed sheet with an advanced textile, lifting device, may positively impact concordance with repositioning protocols, improve tissue microclimate and so improve patient outcomes and, importantly, caregiver safety.

Стилі APA, Harvard, Vancouver, ISO та ін.

Yadav, Kamlesh Kumar, Khader Shameer, Ben Readhead, Jennifer A. Stockert, Cordelia Elaiho, Shalini S. Yadav, Benjamin S. Glicksberg, et al. "Abstract 3250: Computational drug repositioning and biochemical validation of piperlongumine as a potent therapeutic agent for neuroendocrine prostate cancer." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3250.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wathieu, H., K. Cox-Flaherty, R. S. Wang, N. Singh, G. L. Baird, R. Sanders, M. Pereira, et al. "Individualized Interactomes Derived from Pulmonary Endothelial Transcriptomics Collected at Point-of-Care Personalize Therapeutic Repositioning in Pulmonary Arterial Hypertension." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2749.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Viscuso, Stefano, Lorenzo Garavaglia, and Simone Pittaccio. "A Neuro-Mechanical Model Comparing Traditional and Pseudoelastic Splinting of Spastic Joints." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80240.

Повний текст джерела

Анотація:

Neuromuscular rehabilitation of patients with upper motor neuron syndromes (traumatic brain injury - TBI, stroke, cerebral palsy…) is based on multidisciplinary approaches aiming at preventing or contrasting the detrimental sequelae of paresis, contracture and spasticity. Due to the large individual variability of patients’ conditions and impairments it is generally difficult to have a quantitative grasp of the appropriate line of action to prescribe bracing in the most effective manner. This is an even more complex task when testing new therapeutic principles and using non-standardized devices. To this end, it is important to evaluate both instantaneous interaction (orthosis compliance to patient’s movement, localized pressure on the skin, reflex responses, etc.) and mid-long term evolution of the ill-posture (resting angle, reflex adaptation, range of motion, etc.). Accordingly, the current paper presents a model devised to investigate the interaction between the human body and two main types of othotic devices: traditional and pseudoelastic Ni-Ti based orthoses. The two devices represent different approaches to repositioning: traditional braces impose a joint angle and expect plastic relaxation, while pseudoelastic splints promote a plastic creep of tissues towards a more physiological posture without forcing the joints into any particular position. This idea has already been described in previous work [1] and ad-hoc devices have been constructed [2]. The focus here is on possible application scenarios.

Стилі APA, Harvard, Vancouver, ISO та ін.

Hirasawa, Akira, Astrid Murumägi, Mariliina Arjama, Bhagwan Yadav, John Patrick Mpindi, Krister Wennerberg, Tero Aittokallio, Daisuke Aoki, and Olli Kallioniemi. "Abstract POSTER-TECH-1111: High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs." In Abstracts: 10th Biennial Ovarian Cancer Research Symposium; September 8-9, 2014; Seattle, WA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.ovcasymp14-poster-tech-1111.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Karsa, M., T. Failes, GM Arndt, UR Kees, M. Haber, MD Norris, R. Sutton, RB Lock, K. Somers, and MJ Henderson. "PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.431.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Imakura, T., S. Sato, K. Koyama, H. Ogawa, T. Niimura, K. Murakami, Y. Yamashita, et al. "Computational Drug Repositioning Approach Identifies Polo-Like Kinase Inhibitors as Potential Therapeutics for Pulmonary Fibrosis." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1956.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wu, Xiaojuan, Hui Xiao, Chenglong Li, and Jiayuh Lin. "Abstract A177: Repositioning Bazedoxifene as a novel inhibitor of IL-6/GP130 signaling for pancreatic cancer therapy." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-a177.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!